159 related articles for article (PubMed ID: 27668043)
21. Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.
Chehab S; Panjic EH; Gleason C; Lonial S; Nooka AK
Future Oncol; 2018 Dec; 14(30):3111-3121. PubMed ID: 30136602
[TBL] [Abstract][Full Text] [Related]
22. Proteasome inhibition and its therapeutic potential in multiple myeloma.
Chari A; Mazumder A; Jagannath S
Biologics; 2010 Sep; 4():273-87. PubMed ID: 21116326
[TBL] [Abstract][Full Text] [Related]
23. 2023 FDA approvals: unprecedented volume at moderate value.
Baedeker M; Ringel MS; Möller CC
Nat Rev Drug Discov; 2024 Feb; 23(2):98. PubMed ID: 38233681
[No Abstract] [Full Text] [Related]
24. Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018.
Ribeiro TB; Buss L; Wayant C; Nobre MRC
PLoS One; 2020; 15(7):e0236345. PubMed ID: 32706800
[TBL] [Abstract][Full Text] [Related]
25. Biomarkers for Precision Patient Selection in Cancer Therapy Approvals in the US, from 2011 to 2023.
Dou YN; Grimstein C; Mascaro J; Wang J
Clin Pharmacol Ther; 2024 May; ():. PubMed ID: 38747390
[TBL] [Abstract][Full Text] [Related]
26. FDA Approvals of Oncology Drugs for Tissue-Agnostic Indications.
Zettler ME
Target Oncol; 2023 Sep; 18(5):777-792. PubMed ID: 37477750
[TBL] [Abstract][Full Text] [Related]
27. By the Numbers: Percent Share of Novel FDA Drug Approvals in Four Major Therapeutic Categories, 1980-2018.
Cancer Discov; 2019 Nov; 9(11):1477. PubMed ID: 31676559
[TBL] [Abstract][Full Text] [Related]
28. Race and Ethnicity Reporting and Enrollment Disparities in Clinical Trials Leading to FDA Approvals for Breast Cancer Between 2010 and 2020.
Nguyen RH; Silva Y; Lu J; Chen Z; Gadi V
Clin Breast Cancer; 2023 Aug; 23(6):591-597. PubMed ID: 37296063
[TBL] [Abstract][Full Text] [Related]
29. New Medical Device and Therapeutic Approvals in Otolaryngology: State of the Art Review of 2021.
Choi AM; Brenner MJ; Gorelik D; Erbele ID; Crowson MG; Kadkade P; Takashima M; Santa Maria PL; Hong RS; Rose AS; Ostrander BT; Rabbani CC; Morrison RJ; Weissbrod PA; Tate AD; Kain JJ; Lina IA; Shaffer SR; Ahmed OG
OTO Open; 2022; 6(3):2473974X221126495. PubMed ID: 36171808
[TBL] [Abstract][Full Text] [Related]
30. Recent drug approvals from the US FDA and EMEA: what the future holds.
Pevarello P
Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069
[TBL] [Abstract][Full Text] [Related]
31. Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021.
Daval CJR; Teng TW; Russo M; Kesselheim AS
JAMA Health Forum; 2023 Jul; 4(7):e231718. PubMed ID: 37418270
[TBL] [Abstract][Full Text] [Related]
32. Patient-reported outcome claims in European and United States orphan drug approvals.
Jarosławski S; Auquier P; Borissov B; Dussart C; Toumi M
J Mark Access Health Policy; 2018; 6(1):1542920. PubMed ID: 30425804
[No Abstract] [Full Text] [Related]
33. Quantifying Clinical Trial Diversity in Pivotal Registration Trials of FDA Novel Drug Approvals.
Idris MY; Fitzsimmons WE; Pemu P
Ther Innov Regul Sci; 2024 Jan; 58(1):175-183. PubMed ID: 37872439
[TBL] [Abstract][Full Text] [Related]
34. The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications.
Purpura CA; Garry EM; Honig N; Case A; Rassen JA
Clin Pharmacol Ther; 2022 Jan; 111(1):135-144. PubMed ID: 34726771
[TBL] [Abstract][Full Text] [Related]
35. Insights into the FDA 2018 New Drug Approvals.
Bedair A; Mansour FR
Curr Drug Discov Technol; 2021; 18(2):293-306. PubMed ID: 31793428
[TBL] [Abstract][Full Text] [Related]
36. Oligonucleotides to the (Gene) Rescue: FDA Approvals 2017-2019.
Rüger J; Ioannou S; Castanotto D; Stein CA
Trends Pharmacol Sci; 2020 Jan; 41(1):27-41. PubMed ID: 31836192
[TBL] [Abstract][Full Text] [Related]
37. Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021.
Martins AC; Oshiro MY; Albericio F; de la Torre BG; Pereira GJV; Gonzaga RV
Biomedicines; 2022 Sep; 10(9):. PubMed ID: 36140426
[TBL] [Abstract][Full Text] [Related]
38. Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action.
Olivier T; Haslam A; Prasad V
JAMA Netw Open; 2021 Dec; 4(12):e2138793. PubMed ID: 34905002
[TBL] [Abstract][Full Text] [Related]
39. Investigating Rates of Food and Drug Administration Approvals and Guidances in Drug Development: A Structural Breakpoint/Cointegration Timeseries Analysis.
Daizadeh I
Ther Innov Regul Sci; 2020 Sep; 54(5):1056-1067. PubMed ID: 32006390
[TBL] [Abstract][Full Text] [Related]
40. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
Anderson LD
Future Oncol; 2022 Jan; 18(3):277-289. PubMed ID: 34854741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
